Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE

BACKGROUND: MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 weeks. Both studies showed sustained and clinically m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hupperts, Raymond, Gasperini, Claudio, Lycke, Jan, Ziemssen, Tjalf, Feys, Peter, Xiao, Shan, Acosta, Carlos, Koster, Thijs, Hobart, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121513/
https://www.ncbi.nlm.nih.gov/pubmed/35601756
http://dx.doi.org/10.1177/17562864221090398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121513/
https://www.ncbi.nlm.nih.gov/pubmed/35601756
http://dx.doi.org/10.1177/17562864221090398

Ejemplares similares